Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325402 | 1.00 | POLB (0.39) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL7273731 | 1.00 | POLB (0.39) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL1933031 | 1.00 | POLB (0.39) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL7325409 | 1.00 | POLB (0.39) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL2371479 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL9112735 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL2371475 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL19526286 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL2370535 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 | |
| SCHEMBL2371471 | 0.82 | GABRR1 (0.48) | POLBALDH1A1LMNAGABRR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7188099-A | — | — | None | — | — | JP | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3497103-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | Pfizer Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| EP-0384380-B1 | Novel peptide derivatives and their pharmaceutical use | JAPAN TOBACCO INC (JP) | 1996-06-19 | — | — | EP | disclosed |
| EP-0473993-B1 | Novel peptide derivatives and their pharmaceutical use | JAPAN TOBACCO INC (JP) | 1996-04-17 | — | — | EP | disclosed |
| JP-H07188099-A | PRODUCTION OF (1S,2R)-4-OXO-2-METHYLCYCLOPENTANECARBOXYLIC ACID AND ITS DERIVATIVE | JAPAN TOBACCO INC | 1995-07-25 | — | — | JP | disclosed |
| US-5151497-A | Central nervous system disorders, antidepressants, epilepsy and cognition activators | JAPAN TOBACCO INC. (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0473993-A2 | Novel peptide derivatives and their pharmaceutical use | Japan Tobacco Inc. (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0384380-A2 | Novel peptide derivatives and their pharmaceutical use | JAPAN TOBACCO INC. (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | POLB 316/4885ALDH1A1 3667/4885LMNA 2249/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | POLB 300/4885ALDH1A1 3720/4885LMNA 2211/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | POLB 300/4885ALDH1A1 3720/4885LMNA 2211/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | POLB 300/4885ALDH1A1 3720/4885LMNA 2211/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | POLB 300/4885ALDH1A1 3720/4885LMNA 2211/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | POLB 300/4885ALDH1A1 3720/4885LMNA 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.